A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
Recruiting now · Phase 4
Conditions studied: COVID-19 Vaccines
In brief
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough). The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines. Participants will be in the study for about 12 months.
Key facts
- Study ID
- NCT07730450
- Run by
- BioNTech SE
- People needed
- 200
- Starts
- 2026-07-23
- Expected to finish
- 2027-08-20
- Last updated by the study team
- 2026-08-07
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.
Where it is running
- Diablo Clinical Research, LLC dba Flourish Research — Walnut Creek, California, United States (enrolling)
- Palm Springs Community Health Center — Miami Lakes, Florida, United States (enrolling)
- East-West Medical Research Institute — Honolulu, Hawaii, United States (enrolling)
- Duke Vaccine and Trials Unit — Durham, North Carolina, United States (enrolling)
- J. Lewis Research, Inc. / Foothill Family Clinic — Salt Lake City, Utah, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.